Consensus Ligand Pharmaceuticals Incorporated

Stocks

LGND

US53220K5048

Pharmaceuticals

Real-time Estimate Cboe BZX 14:30:39 2026-10-05 EDT			5-day change	1st Jan Change
308.12 ^USD	+1.70%		-1.86%	+63.05%

09-25	Barclays Initiates Ligand Pharmaceuticals at Overweight With $345 Price Target	MT
09-24	Ligand Pharmaceuticals Invests Up to $47 Million in AvenCell	MT

Evolution of the Average Target: Ligand Pharmaceuticals Incorporated

Evolution of the Target Price: Ligand Pharmaceuticals Incorporated

Changes in Analyst Recommendations: Ligand Pharmaceuticals Incorporated

64c748596bff5c6083f4aa3599c479c.nodriTSjoZY9qlz21J4NW-IDgp3QXHRDMWr4TMBVL9Y.9tZYxFLu2-5-zB24ttZ_Eos6-tvkPyQmWgGIGKQ-fLj43gG5YMHb70f-ZA~c305f586159f2ebd9a5ab811a8b3901a

Analysts' recommendations: Ligand Pharmaceuticals Incorporated

09-25	Barclays Initiates Ligand Pharmaceuticals at Overweight With $345 Price Target	MT
08-07	RBC Adjusts PT on Ligand Pharmaceuticals to $345 From $340, Maintains Outperform Rating	MT
08-03	Oppenheimer Adjusts Ligand Pharmaceuticals PT to $326 From $285, Maintains Outperform Rating	MT
07-15	RBC Capital Adjusts Price Target on Ligand Pharmaceuticals to $340 From $262, Maintains Outperform Rating	MT
05-28	BofA Securities Adjusts Ligand Pharmaceuticals Price Target to $266 From $263	MT
05-08	RBC Raises Price Target on Ligand Pharmaceuticals to $262 From $252, Keeps Outperform Rating	MT
04-28	RBC Raises Price Target on Ligand Pharmaceuticals to $252 From $235, Keeps Outperform Rating	MT
03-30	RBC Raises Price Target on Ligand Pharmaceuticals to $64 From $48, Keeps Outperform Rating	MT
03-11	BofA Securities Initiates Ligand Pharmaceuticals at Buy With $244 Price Target	MT
02-27	Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $277 From $275, Maintains Outperform Rating	MT
12-10	RBC Lifts Price Target on Ligand Pharmaceuticals to $235 From $234, Keeps Outperform Rating	MT
12-09	Citigroup Initiates Ligand Pharmaceuticals at Buy With $270 Price Target	MT
11-25	Ligand Pharmaceuticals Expected to Issue Conservative 2026 Outlook at Upcoming Investor Day, RBC Says	MT
11-10	RBC Raises Price Target on Ligand Pharmaceuticals to $234 From $185, Keeps Outperform Rating	MT
11-03	Oppenheimer Raises Price Target on Ligand Pharmaceuticals to $250 From $190, Keeps Outperform Rating	MT
25-09-03	Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $190 From $167, Maintains Outperform Rating	MT
25-05-09	Oppenheimer Adjusts Ligand Pharmaceuticals Price Target to $145 From $142, Maintains Outperform Rating	MT
25-04-10	Stifel Initiates Ligand Pharmaceuticals at Buy With $143 Price Target	MT
25-02-28	Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $142 From $151, Maintains Outperform Rating	MT
25-02-28	RBC Raises Price Target on Ligand Pharmaceuticals to $155 From $143, Keeps Outperform Rating	MT
24-12-11	Oppenheimer Adjusts Ligand Pharmaceuticals Price Target to $151 From $135, Maintains Outperform Rating	MT
24-12-11	RBC Raises Price Target on Ligand Pharmaceuticals to $143 From $141, Keeps Outperform Rating	MT
24-12-03	RBC Lifts Price Target on Ligand Pharmaceuticals to $141 From $140, Keeps Outperform Rating	MT
24-11-08	Oppenheimer Adjusts Ligand Pharmaceuticals Price Target to $147 From $135, Maintains Outperform Rating	MT
24-10-03	Oppenheimer Initiates Ligand Pharmaceuticals at Outperform With $135 Price Target	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	LIGAND PHARMACEUTICALS INCORPORATED					+13.63%
	ELI LILLY AND COMPANY					+16.27%
	JOHNSON & JOHNSON					+9.08%
	ABBVIE INC.					+6.1%
	MERCK & CO., INC.					+7.94%
	ROCHE HOLDING AG					+8.57%
	NOVARTIS AG					+8.14%
	ASTRAZENECA PLC					+34.02%
	AMGEN INC.					-3%
	GILEAD SCIENCES, INC.					+9.61%
	Average					+11.04%
	Weighted average by Cap.					+11.43%